Icenticaftor is under clinical development by Novartis and currently in the Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.
According to GlobalData, the latest event to affect Icenticaftor’s likelihood of approval (LoA) and phase transition for Chronic Obstructive Pulmonary Disease (COPD) took place on 18 Aug 2021, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.
GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Icenticaftor Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.
Icenticaftor is under development for the treatment of chronic obstructive pulmonary disease (COPD) and bronchiectasis. The drug candidate is administered orally. It acts by targeting CFTR. It was also under development for cystic fibrosis.
Novartis is a healthcare company that focuses on the discovery, development, manufacture and marketing of prescription and generic pharmaceutical products and eye care products. It provides drugs for the treatment of cancer, cardiovascular diseases, dermatological conditions, neurological disorders, ophthalmic and respiratory diseases, immune disorders, and infections, among others. The company offers generic medicines and biosimilars through Sandoz. Novartis conducts research in various disease areas through The Novartis Institutes for BioMedical Research (NIBR). The company operates through a network of subsidiaries and offices across the Americas, Europe, the Middle East, Africa, and Asia-Pacific. Novartis is headquartered in Basel, Switzerland.
Quick View Icenticaftor LOA Data
|Highest Development Stage|